Aclaris starts phase 1 trial for ATI-50001 to treat alopecia totalis and alopecia universalis

Source: Aclaris Therapeutics' investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review period by the US Food and Drug Administration, allowing the company to go ahead with its planned…...

Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206

Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced top-line results from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV. The highest dose tested, SB206 12%, demonstrated a statistically significant improvement (p<0.05) in the incidence…...